RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
More RSI News
Best Practices for Consideration of the Effects of Climate Change in Project-Level Assessments
Risk Sciences International (RSI) is pleased to announce in collaboration with the Ontario Centre for Climate Impacts and Adaptation Resources (OCCIAR), the public release of…
Risks of anticholinergic drugs
Adverse effects of drugs among the elderly should be given special attention when considering a pharmacological intervention. Two recent papers using large electronic health records…
Dr. Emma Hartnett Selected for JEMRA Roster of Scientific Experts
RSI’s Emma Hartnett has been selected to be part of the Joint FAO/WHO Expert Meetings on Microbiological Risk Assessment (JEMRA) Roster of Experts for a…
Training Seminar in Systematic Review
RSI recently conducted an in-house training session in systematic review for its staff. The session featured a keynote presentation by Dr. Katya Tsaioun from Johns…